Welcome to our dedicated page for Aquestive Therapeutics SEC filings (Ticker: AQST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind Aquestive Therapeutics’ film-based drug delivery breakthroughs? Our SEC filings hub connects the dots between headline-grabbing pipeline news and the hard numbers hidden in 10-K annual reports. With Stock Titan’s AI, understanding Aquestive Therapeutics SEC documents with AI means you can spot clinical-trial expenses, royalty revenue, and burn-rate trends without wading through jargon-heavy pages.
Need specific updates? Real-time alerts surface Aquestive Therapeutics Form 4 insider transactions real-time, so you see management’s moves as they happen. The same dashboard clarifies every Aquestive Therapeutics quarterly earnings report 10-Q filing, highlights cash-flow shifts, and provides concise Aquestive Therapeutics earnings report filing analysis. Material announcements get equal attention—our summaries make each Aquestive Therapeutics 8-K material events explained in plain language.
For deeper dives, open any document and let the platform answer questions you’d normally send to an analyst:
- Aquestive Therapeutics insider trading Form 4 transactions – follow executive buy & sell patterns.
- Aquestive Therapeutics proxy statement executive compensation – unpack pay structures, option grants, and dilution risk.
- Aquestive Therapeutics annual report 10-K simplified – see timelines for CNS and anaphylaxis programs.
- Aquestive Therapeutics executive stock transactions Form 4 – monitor confidence before trial readouts.
Whether you’re preparing a valuation model or simply checking risk factors, Stock Titan’s AI-powered summaries, expert context, and comprehensive coverage turn dense biotech disclosures into actionable insight—no PhD required.
Aquestive Therapeutics (AQST) Chief Operating Officer reported transactions on 10/15/2025. The officer exercised 25,000 non-qualified stock options at a $3.1027 exercise price (code M) and sold 67,575 shares at an average price of $7.01 (code S), pursuant to a Rule 10b5-1 trading plan.
Following the transactions, the officer beneficially owned 240,771 shares directly and 2,000 shares indirectly by spouse. The reported option, granted on June 10, 2021, is fully vested and shows 0 derivative securities remaining after the exercise.
Aquestive Therapeutics (AQST) reported an insider transaction: the Chief Medical Officer sold 20,272 shares of common stock on 10/15/2025 at a weighted average price of $7.00, with individual trades ranging from $7.00 to $7.02, executed under a Rule 10b5-1 trading plan.
After the transaction, the reporting person beneficially owned 282,475 shares, held directly.
Aquestive Therapeutics (AQST) reported an insider transaction on a Form 4. An officer sold 10,000 shares of common stock at $7 on 10/15/2025, reported with transaction code S.
The filing states the sales were effected pursuant to a previously adopted Rule 10b5-1 trading plan. Following the transaction, the reporting person beneficially owns 268,323 shares, held directly. The officer’s title is SVP IT, HR, & Communications.
Daniel Barber, President and CEO and a director of Aquestive Therapeutics (AQST), reported the sale of 91,343 shares on 09/26/2025 under a previously adopted Rule 10b5-1 trading plan. The sales were executed at prices ranging from $6.00 to $6.11 per share, with a weighted average price of $6.0343. After the reported transactions, Mr. Barber beneficially owned 923,430 shares. The filer notes they will provide, upon request, details on the number of shares sold at each separate price.
Aquestive Therapeutics (AQST) insider sale: Peter E. Boyd, an officer serving as SVP IT, HR & Communications, reported a sale of 10,000 shares of the company’s common stock on 09/26/2025 at a price of $6.30 per share. After the transaction he beneficially owned 278,323 shares. The filing states the sales were effected under a previously adopted Rule 10b5-1 trading plan. The Form 4 was signed by attorney-in-fact Lori Braender on 09/29/2025.
Aquestive Therapeutics (AQST) Form 144: A notice reports a proposed sale of 10,000 shares of the issuer's common stock through Merrill on 09/26/2025 with an aggregate market value of $63,000. The company has 99,723,635 shares outstanding, per the form. The shares to be sold were originally acquired via a stock option that vested on 05/11/2018 (acquisition amount recorded as 49,439 shares). The filing also discloses a recent sale by Peter Boyd of 15,000 shares on 09/05/2025 for gross proceeds of $79,500. The filer affirms no undisclosed material adverse information and includes the standard Rule 144 and 10b5-1 representations.
Aquestive Therapeutics insider sale notice: The filer intends to sell 91,343 shares of common stock through Morgan Stanley Smith Barney, with an approximate sale date of 09/26/2025 and an aggregate market value reported at $480,464.18. The shares were acquired on 06/08/2022 in a private acquisition from the issuer, and payment was made in cash. The filing reports 99,723,635 shares outstanding for the class. The form also discloses a recent 10b5-1 sale of 400 shares on 09/19/2025 for $2,400.00. The filer represents there is no undisclosed material adverse information and references compliance with Rule 10b5-1 where applicable.
Daniel Barber, President & CEO and director of Aquestive Therapeutics (AQST), reported a sale of common stock executed on 09/19/2025. The Form 4 shows 400 shares were disposed of at $6.00 per share under a previously adopted Rule 10b5-1 trading plan.
The filing reports that after the sale Barber beneficially owns 1,014,773 shares. The Form 4 was submitted by one reporting person and signed on behalf of Barber by an attorney-in-fact, Lori Braender, on 09/22/2025.
FAQ
What is the current stock price of Aquestive Therapeutics (AQST)?
What is the market cap of Aquestive Therapeutics (AQST)?
